近畿大学  呼吸器・
アレルギー内科学教室

ABOUT

MOBILE QR CODE

携帯のバーコードリーダーでQRコードを読み取ることで、携帯版ホームページへアクセスできます。

Research Achievements

♬♬♬♬

Department of Respiratory Medicine & Allergology
Kindai University Faculty of Medicine

2021年

1                Yamazaki R, Nishiyama O, Yoshikawa K, et al. HFpEF without elevated right ventricular systolic pressure is a favorable prognostic indicator in patients with IPF requiring hospitalization for heart failure. PLoS One. 2021; 16: e0245778.

2                Yamazaki R, Nishiyama O, Yoshikawa K, et al. Clinical course and prognosis in survivors of acute exacerbations of idiopathic pulmonary fibrosis. Respir Investig. 2021; 59: 408-13.

3                Yamazaki R, Nishiyama O, Yoshikawa K, et al. Comparison of CURB-65, PSI, and qSOFA for predicting pneumonia mortality in patients with idiopathic pulmonary fibrosis. Sci Rep. 2021; 11: 3880.

4                Yamazaki R, Nishiyama O, Saeki S, et al. Initial therapeutic dose of corticosteroid for an acute exacerbation of IPF is associated with subsequent early recurrence of another exacerbation. Sci Rep. 2021; 11: 5782.

5                Yamazaki R, Nishiyama O, Gose K, et al. Pneumothorax in patients with idiopathic pulmonary fibrosis: a real-world experience. BMC Pulm Med. 2021; 21: 5.

6                Sunadome H, Matsumoto H, Tohda Y, et al. Assessment of serum periostin level as a predictor of requirement for intensive treatment for type-2 inflammation in asthmatics in future: A follow-up study of the KiHAC cohort. Allergol Int. 2021; 70: 252-4.

7                Sugiya R, Higashimoto Y, Shiraishi M, et al. Decreased Tongue Strength is Related to Skeletal Muscle Mass in COPD Patients. Dysphagia. 2021.

8                Nishiyama O, Shimizu S, Haratani K, et al. Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. BMC Pulm Med. 2021; 21: 155.

9                Muraki M, Kunita Y, Shirahase K, et al. A randomized controlled trial of long-acting muscarinic antagonist and long-acting beta2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease. BMC Pulm Med. 2021; 21: 26.

10              Iwanaga T, Tanaka H, Hozawa S, et al. A questionnaire validated using local treatment guidelines may better predict future asthma risk: MARGIN study. Respir Investig. 2021.

11              Higashimoto Y, Shiraishi M, Sugiya R, et al. Effect of Pulmonary Rehabilitation on Erector Spinae Muscles in Individuals With COPD. Respir Care. 2021.

12              Heaney LG, Perez de Llano L, Al-Ahmad M, et al. Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort. Chest. 2021.

13              Tashima N, Matsumoto H, Nomura N, et al. Airway clearance ameliorated the control of diffuse panbronchiolitis accompanied by asthma and leukocytoclastic vasculitis. Allergol Int. 2021; 70: 131-3.

14              Tanabe N, Sato S, Oguma T, et al. Influence of Asthma Onset on Airway Dimensions on Ultra-high-resolution Computed Tomography in Chronic Obstructive Pulmonary Disease. J Thorac Imaging. 2021; 36: 224-30.

15              Tanabe N, Matsumoto H, Hamada S, et al. Dupilumab maintenance therapy in an asthmatic patient with coronavirus disease 2019 pneumonia. Allergol Int. 2021; 70: 274-6.

16              Sunadome H, Sato S, Matsumoto H, et al. Similar distribution of peripheral blood eosinophil counts in European and East Asian populations from investigations of large-scale general population studies: the Nagahama Study. Eur Respir J. 2021; 57.

17              Shirata M, Ito I, Tanabe N, et al. Risk factors associated with methicillin-resistant Staphylococcus aureus isolation from serially collected sputum samples of patients hospitalized with pneumonia. J Infect Chemother. 2021.

18              Sato R, Handa T, Matsumoto H, et al. Antitussive effect of a chest band in patients with interstitial lung disease: preliminary results from a pre-post intervention study. Int Med. 2021; in press.

19              Oi I, Ito I, Hirabayashi M, et al. Pneumonia caused by severe acute respiratory syndrome coronavirus 2 and influenza virus: A multicenter comparative study. Open Forum Inf Dis. 2021;8(7):ofab282.

20              Niwamoto T, Handa T, Matsui S, et al. Phenotyping of IgG4-related diseases based on affected organ pattern: A multicenter cohort study using cluster analysis. Mod Rheumatol. 2021; 31: 235-40.

21              Nagase H, et al. The prevalence of comorbid respiratory disease among COVID-19 patients, and mortality during the first wave in Japan: A nationwide survey by the Japanese Respiratory Society. Respir Investig. 2021; 59(5):679-682.

22              Morimoto C, Matsumoto H, Nagasaki T, et al. Gastroesophageal reflux disease is a risk factor for sputum production in the general population: the Nagahama study. Respir Res. 2021; 22: 6.

23              Matsunaga K, Kuwahira I, Hanaoka M, et al. An official JRS statement: The principles of fractional exhaled nitric oxide (FeNO) measurement and interpretation of the results in clinical practice. Respir Investig. 2021; 59: 34-52.

24              Kitazawa H, Hizawa N, Nishimura Y, et al. The impact of the COVID-19 pandemic on asthma treatment in Japan: Perspectives based on doctors' views. Respir Investig. 2021.

25              Kogo M, Matsumoto H, Tanabe N et al. The importance of central airway dilatation in patients with bronchiolitis obliterans. ERJ Open Res 2021 in press. ERJ Open Res. 2021; 7(4):00123.
26              Matsuhira T, Nishiyama O, Chiba Y, et al. Comprehensive analysis of cytokines in bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis: a cross-sectional study. Acta Med Kindai Univ. 2021; 46:1-7
27              Nishiyama O, Kataoka K, Ando M, et al. Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis. ERJ Open Res. 2021;7(3):00321
28              Tanabe N, Kumamaru H, Tamura Y, et al. Multi-Institutional Prospective Cohort Study of Patients With Pulmonary Hypertension Associated With Respiratory Diseases. Circulation Journal. 2021;85(4):333-342
29              白波瀬 賢,西山 理,大森 隆,他.アスベスト肺の経過中に発症した多発血管炎性肉芽腫症の1例.日呼吸誌, 2021;10(2):178-182
30              白石 ,東本 有司,杉谷 竜司,.横隔膜動態からみた吸気筋トレーニングの適正負荷圧の検討.日本呼吸ケア・リハビリテーション学会誌.2021;29(3):453-459
31              岡島 聡,前田 和成,東本 有司,他. 高齢呼吸器疾患患者の呼吸ケアー認知機能障害に対する対応―.日本呼吸ケア・リハビリテーション学会誌2021;29(3):263-368.
32              Matsuhira T, Nishiyama O, Tabata Y, et al. The phosphodiesterase 4 inhibitor AA6216 suppresses activity of fibrosis-specific macrophages. Biochem Biophys Rep.2021;28:101118.
33              Kondoh Y, Makino S, Ogura T, et al. 2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. 2021; Respir Investig.2021;59(6):709-740.
34              Shiraishi M, Higashimoto Y, Sugiya R, Diaphragmatic excursion is correlated with the improvement in exercise tolerance after pulmonary rehabilitation in patients with chronic obstructive pulmonary disease.2021; Respir Res.22;22(1):271
35              Saeki S, Nishiyama O,Yamazaki R, et al. Effect of antifibrotic agents on survival in idiopathic pulmonary fibrosis patients according to forced vital capacity: a real-world retrospective cohort study in Japan.Acta Med Kindai Univ.2021;-46(2): 57-64
36              松本 久子.重症喘息の病態解明と個別化治療への展開.近畿大医誌.2021;46(3-4):63-71
37              Tohda Y, Matsumoto H, Miyata M, et al. Cost-effectiveness analysis of dupilumab among patients with oral corticosteroid-dependent uncontrolled severe asthma in Japan. Journal of Asthma.2021;8:1-12

2020年

1                Yamazaki R, Nishiyama O, Saeki S, et al. Characteristics of patients with chronic idiopathic interstitial pneumonia undergoing repeated respiratory-related hospitalizations: A retrospective cohort study. PLoS One. 2020; 15: e0232212.

2                Tohda Y, Nakamura Y, Fujisawa T, et al. Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study. Allergol Int. 2020; 69: 578-87.

3                Tanaka A, Tohda Y, Okamiya K, et al. Efficacy and Safety of HDM SLIT Tablet in Japanese Adults with Allergic Asthma. J Allergy Clin Immunol Pract. 2020; 8: 710-20 e14.

4                Sunadome H, Matsumoto H, Tohda Y, et al. Assessment of serum periostin level as a predictor of requirement for intensive treatment for type-2 inflammation in asthmatics in future: A follow-up study of the KiHAC cohort. Allergol Int. 2020; 70: 252-4.

5                Shiraishi M, Higashimoto Y, Sugiya R, et al. Diaphragmatic excursion correlates with exercise capacity and dynamic hyperinflation in COPD patients. ERJ Open Res. 2020; 6.

6                Sano A, Sano H, Iwanaga T, et al. Functional role of phosphatidylcholine-specific phospholipase C in regulating leukotriene synthesis and degranulation in human eosinophils. Eur J Pharmacol. 2020; 884: 173353.

7                Nishikawa Y, Nishiyama O, Shimizu S, et al. Wandering pulmonary shadows coinciding with pericardial and pleural effusions. Thorax. 2020; 75: 817-8.

8                Nakamura Y, Tamaoki J, Nagase H, et al. Japanese guidelines for adult asthma 2020. Allergol Int. 2020; 69: 519-48.

9                Nagase H, Adachi M, Matsunaga K, et al. Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan. Allergol Int. 2020; 69: 53-60.

10              Matsunaga K, Adachi M, Nagase H, et al. Association of low-dosage systemic corticosteroid use with disease burden in asthma. NPJ Prim Care Respir Med. 2020; 30: 35.

11              Matsuhira T, Nishiyama O, Tabata Y, et al. A novel phosphodiesterase 4 inhibitor, AA6216, reduces macrophage activity and fibrosis in the lung. Eur J Pharmacol. 2020; 885: 173508.

12              Kondoh Y, Azuma A, Inoue Y, et al. Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Randomized, Double-Blind Placebo-controlled Trial. Am J Respir Crit Care Med. 2020; 201: 1110-9.

13              Iwanaga T, Tohda Y. [the Jrs Guidelines 2019 for the Management of Refractory Asthma]. Arerugi. 2020; 69: 8-12.

14              Higashimoto Y, Sano A, Nishiyama O, et al. Prefrontal cortex activation is associated with dyspnea during methacholine bronchial provocation tests in patients with bronchial asthma. Allergol Int. 2020; 69: 453-4.

15              Higashimoto Y, Ando M, Sano A, et al. Effect of pulmonary rehabilitation programs including lower limb endurance training on dyspnea in stable COPD: A systematic review and meta-analysis. Respir Investig. 2020; 58: 355-66.

16              FitzGerald JM, Tran TN, Alacqua M, et al. International severe asthma registry (ISAR): protocol for a global registry. BMC Med Res Methodol. 2020; 20: 212.

17              Castro M, Rabe KF, Corren J, et al. Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma. ERJ Open Res. 2020; 6.

18              Asano K, Sagara H, Ichinose M, et al. A Phase 2a Study of DP2 Antagonist GB001 for Asthma. J Allergy Clin Immunol Pract. 2020; 8: 1275-83 e1.
19              杉谷 竜司,西山 理,白石 匡,他.横隔神経麻痺を合併した小児に対し吸気筋トレーニングが有効であった1例.日本呼吸ケア・リハビリテーション学会誌2020;28(3):484-487

CONTACT

PAGE TOP